August 17, 2017
A Florida federal judge granted pharmaceutical manufacturer Patheon Inc.'s request Thursday for $18.5 million in attorneys' fees and defense costs related to former joint venture partner Procaps SA's $255 million antitrust suit, which the court said was "especially unpleasant and nasty."
October 30, 2015
A Florida federal judge on Thursday put an end to Procaps' suit accusing pharmaceutical company and its former joint venture partner Patheon of creating antitrust issues by purchasing one of Procaps' rivals for $255 million, saying Procaps couldn't show that any actual competitive harm had occurred.
July 21, 2015
A Florida federal magistrate judge on Monday ordered Procaps SA's attorneys to pay $25,000 in attorneys' fees to Patheon Inc. after finding they had overdesignated discovery documents as "highly confidential" in Procaps' antitrust suit against former joint venture partner Patheon over its $255 million acquisition of a pharmaceutical company.
June 03, 2014
Procaps SA on Monday won some of the attorneys' fees it requested against former joint venture partner Patheon Inc. and the pharmaceutical company's counsel, Cooley LLP, over a vendor with a conflict of interest in Procaps' suit, which claimed Patheon's $255 million merger creates antitrust issues for its former partner.
January 29, 2014
Pharmaceutical company Patheon Inc. lost a bid to shut down a suit by former joint venture partner Procaps SA on Wednesday, when a Florida federal judge determined Procaps hadn't been the sole cause of its own entanglement in antitrust issues as a result of a separate $255 million merger by Patheon.
February 25, 2013
A Florida federal judge said Friday that Procaps SA can contest joint venture partner Patheon Inc.'s $255 million acquisition of a pharmaceutical company, shooting down Patheon's argument that Procaps actually stood to benefit from the deal's alleged anti-competitive impacts.
January 15, 2013
Patheon Inc. on Monday urged a Florida federal court to toss a challenge to the company's $255 million acquisition of a pharmaceutical company, saying joint venture partner Procaps SA, which had lodged the antitrust suit, would benefit from the deal's alleged anti-competitive impacts.